Page 12 - Sun Pharma

Sun Pharma acquires Japan's Pola Pharma to expand in dermatology segment

Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables

Sun Pharma up 2% as arm gets relief by US court in patent infringement case

On a year-to-date (YTD) basis, Sun Pharma stock has underperformed the Nifty Pharma index by declining around 28 per cent.

Sun Pharma arm gets relief from US court in patent infringement case

Earlier this year, DUSA, which is wholly-owned by Sun Pharma, filed a lawsuit against the Biofrontera defendants in the US District Court for the District of Massachusetts

Sebi probes whistleblower complaint against Sun Pharma; shares tumble 3%

A whistleblower had last month approached Sebi with a document alleging various irregularities by the company, its promoter Dilip Shanghvi and others

Meet Sudhir Valia, Sun Pharma's director, one of India's prolific investors

His real estate transactions in the last couple of years further bought him into the spotlight

Sun Pharma promoters lose Rs 126 bn in 10 days over insider trading charges

Shares plunge to a five-year low

Sun Pharma hits lowest level since April 2013; falls 33% from 52-week high

The stock hit an over five-year low of Rs 433, down 2%, falling 12% in three days, even though the company made a clarification related to corporate governance and whistleblower issues.

Shadow over Sun Pharma

Firm's response to governance allegations inadequate

Sudhir Valia's Sun Pharma stake helps ARC, realty business raise debt

MFs take exposure to realty arm; guarantee by investment entity gives top rating

Sun Pharma still not out of red; unsecured loan advances among key concerns

Brokerages seem concerned over the whistleblower case and domestic super-stockist distribution structure

Sun Pharma extends fall despite clarification on corporate governance issue

The stock is down 3% at Rs 442 on Tuesday, extending its 7.5% fall on Monday on the BSE.

Sun Pharma shares face turbulent times: Here is how its troubles began

Since November 26, Sun Pharma has lost Rs 133 billion in market capitalisation

Sun Pharma to bring in changes to boost investor confidence, stock falls

Investors also raised questions around loans given to 'employees and others' by the company

Sun Pharma says need more clarity from Sebi about whistle-blower complaint

Sebi has received a 150-page letter in which a whistle-blower has accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations

Sun Pharma slips 8% as Sebi starts probe; may reopen insider trading case

The stock settled 8% lower at Rs 455 on the BSE on reports that the market regulator Sebi has initiated an inquiry into the affairs of pharma major on the basis of a whistle-blower complaint.

Sun Pharma gets US FDA approval for generic Ganirelix Acetate injection

The generic version is therapeutic equivalent to Organon's Ganirelix Acetate injection, 250 mcg/0.5 ml

Sebi starts probe against Sun Pharma, to also reopen insider trading case

The whistle-blower accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations

Sebi may reopen Sun Pharma insider trading case, probe promoters' lapses

According to sources, alleged irregularities by the company's promoters and others in raising funds through FCCBs are also likely to be investigated by the watchdog

Sun Pharma: Governance issues, margin pressures expected to weigh on stock

Sun Pharma's outlook remains muted amid multiple negatives

Sun Pharma shares continue to decline

Sun Pharma stock is yet to recover from Wednesday's fall on the bourses when it hit a six-month low after a foreign brokerage firm raised concerns around corporate governance practices